Key facts
- It has raised $16.7M; the latest was Grant ($7.3M) in Feb 2025.
- Notable investors include Bpifrance, European Commission, La French Tech, Johnson & Johnson JJDC, M Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Astraveus
- ·The full record, as it builds
Funding rounds
No funding rounds for Astraveus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Astraveus
Developer of a cell foundry platform designed to provide affordable biological therapies and minimize environmental impact. The company's platform specializes in building equipment personalized for each patient to utilize autologous cell and gene therapies, along with an automated system for producing autologous biomedicine by using microfluidic chip technology to transform cells into therapeutic agents, enabling the healthcare industry to scale the development and manufacturing of cell and gene therapies at minimal cost and environmental impact.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2016
- Employees
- 44
- Website
- astraveus.com/
- Ownership
- Privately Held (backing)
Astraveus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Astraveus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Astraveus in its N-PORT filings yet. We sweep new filings monthly.